Return to Vaccination News Home Page __» Right-click to "open in new window"
Subscribe to the Vaccination NewsLetter
View past & current Scandals (columns by Sandy Mintz)
Search This Site using keywords
|
|
|||
|
|
|
|
| 1 of 1 |
|
Toxicology
Volume 174, Issue 1 , 15 May 2002, Pages 37-43
| This Document | ||
|
|
Abstract | |
| Full Text + Links | ||
| PDF (100 K) | ||
| Actions | ||
| E-mail Article | ||
![]()
doi:10.1016/S0300-483X(02)00055-0
Cite
or link using doi
Copyright © 2002 Published by Elsevier Science Ireland Ltd. All
rights reserved.
Non-clinical vaccine safety assessment
As vaccines are undoubtedly classified as pharmaceuticals, they have to be submitted to strict non-clinical safety evaluation. The context of their prophylactic use requires that every effort is made to ensure their safe use. Their safety evaluation is complex as they act through a multistage mechanism in which the vaccine by itself acts as a pro-drug, antibodies and activated lymphocytes being the actual effectors. Therefore, several potential toxicities must be considered: direct toxicity of the test article, toxicity linked to the pharmacodynamic activity of the vaccine, activation of pre-existing disorders, toxicity of contaminants and impurities and other adverse reactions due to interaction between the various components. Guidelines dealing with vaccines include general guidelines applicable to all pharmaceuticals, such as ICH S6, and also more specific documents which allow some flexibility in study design. Among the various studies, if single-dose studies are generally part of the quality control test battery, repeated dose studies are pivotal. The animal model and treatment schedule selection and the parameters investigated are critical for the relevance of this safety assessment. Immunological and safety pharmacology parameters should be adapted to the specific properties of vaccines and added to this type of study. Vaccines intended for pregnant women or women of child-bearing age require embryo-fetal and post-natal studies with an adapted design to obtain appropriate fetal and maternal exposure during gestation with continuation into the post-natal period. Tests exist to detect hypersensitivity or autoimmune reactions, but require further validation. In addition to this tailor-made approach, any adjuvant or active component added to the vaccine formulation necessitate their own assessment using studies routinely performed for new drugs. From this review, vaccine toxicology would appear to be a separate discipline on its own whose predictivity will be increased by new method development.
Author Keywords: Vaccine; Non-clinical safety;
Immunotoxicology; Regulatory affairs
|
|
|||||||||||||||||||||||||
Toxicology |
|||||||||||||||||||||||||
| 1 of 1 |
|
|
|
|
| Send
feedback to ScienceDirect Software and compilation © 2003 ScienceDirect. All rights reserved. ScienceDirect® is an Elsevier Science B.V. registered trademark. |
Your use of this service is
governed by
Terms and Conditions. Please review our
Privacy Policy for details on how we protect information that
you supply.
Return to Vaccination News Home Page __» Right-click to "open in new window"
DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.